|
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. SESSION I:
|
|||||||||||||||||||||||||||||||
|
8:40 a.m. |
Workshop Objective: What parameters should be considered when developing a high-impact biomarker? |
|
|
DENNIS CHOI, Workshop Chair Professor of Pharmacology and Experimental Therapeutics Boston University |
|
8:50 a.m. |
Introduction to the fNIH Biomarkers Consortium |
|
|
TOM INSEL Director National Institute of Mental Health |
|
9:10 a.m. |
Lessons Learned from Alzheimer’s Disease and the NIA Alzheimer’s Disease Neuroimaging Initiative |
|
|
WILLIAM POTTER Vice President Merck Research Laboratories Clinical Neuroscience |
SESSION II:
POTENTIAL TOOLS FOR BIOMARKER AND BIOSIGNATURE DEVELOPMENT
Session Objective: Discuss which tools and parameters should be considered when developing a high-impact biomarker for the neurological or psychiatric disorders.
|
|
ALAN BREIER, Session Chair Vice President for Medical and Chief Medical Officer Eli Lilly and Company |
|
9:30 a.m. |
What Impact Will the Genomics Field Have on the Immediate or the Near-Term Development of Biomarkers for Nervous System Diseases? |
|
|
ALLEN ROSES Senior Vice President GlaxoSmithKline |
 |
 |
Page 82 |
 |
 |
 |